AngioDynamics, Inc. - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended November 30, 2009 (Fiscal Q2 2010) and the six months ended November 30, 2009. AngioDynamics, Inc. is a provider of innovative medical devices for minimally invasive, image-guided procedures, organized into three segments: Peripheral Vascular, Access, and Oncology/Surgery. The company operates primarily in the United States, with approximately 11% of sales generated internationally.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2009 | Six Months Ended Nov 30, 2009 |
|---|---|---|
| Net Sales | $53.5 million | $103.6 million |
| Gross Profit | $31.6 million (59.1% margin) | $61.7 million (59.6% margin) |
| Operating Income | $5.3 million (10.0% margin) | $8.9 million (8.6% margin) |
| Net Income | $3.1 million | $5.2 million |
| Diluted EPS | $0.13 | $0.21 |
| Cash & Marketable Securities | $74.0 million (as of Nov 30, 2009) | |
| Total Debt | $6.9 million (as of Nov 30, 2009) | |
| Operating Cash Flow (6mo) | $12.4 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year for the quarter and 12% for the six-month period. Growth was driven by increased unit sales of LC Bead, Benephit renal infusion products (from FlowMedica acquisition), and NanoKnife IRE generators.
- Margin Compression: Gross profit margins declined from 61.3% to 59.1% (quarterly) and 61.6% to 59.6% (six-month). This was attributed to lower average selling prices in the Access segment due to competition and a higher mix of lower-margin LC Bead products in Oncology/Surgery.
- Segment Performance:
- Peripheral Vascular: Sales up 6% (quarter) and 10% (six-month), driven by Benephit and laser ablation products.
- Access: Sales up 4% (quarter) and 4% (six-month), driven by dialysis products.
- Oncology/Surgery: Sales up 28% (quarter) and 27% (six-month), driven by LC Bead, NanoKnife, and Habib devices.
- Expense Management: Operating expenses increased due to investments in R&D (specifically for IRE technology) and expanded sales forces. However, as a percentage of sales, Sales & Marketing and G&A expenses decreased compared to the prior year.
Outlook, Risks, and Contingencies
- Guidance: Management expects R&D expenditures to remain between 9% and 10% of net sales in fiscal 2010 and 2011, primarily due to continued investment in IRE technology.
- Acquisitions: The company completed the acquisition of FlowMedica assets in January 2009. A final payment of $5.0 million was made to Oncobionic in November 2009.
- Litigation:
- AngioDynamics v. Vascular Solutions: Filed in July 2009 alleging patent infringement regarding varicose vein treatment. Vascular Solutions has requested reexamination of the patents.
- AngioDynamics v. biolitec: Seeking indemnification for settled lawsuits; biolitec has filed counter-claims for approximately $1.6 million.
- Key Risks:
- LC Bead Distribution: Exclusive distribution rights expire December 31, 2010. Failure to extend this agreement could materially adversely affect results.
- Healthcare Reform: Potential legislation could impose excise taxes on medical devices or reduce reimbursements.
- Liquidity of Investments: The company holds $1.85 million in auction rate securities that have failed auctions, though issuers remain current on payments.
Investor Verification Checklist
- Verify the status of negotiations to extend the LC Bead distribution agreement beyond December 31, 2010.
- Monitor the progress of the patent infringement lawsuit against Vascular Solutions and the reexamination requests filed with the PTO.
- Assess the impact of potential healthcare reform legislation, specifically excise taxes on medical device sales.
- Review the liquidity status of the $1.85 million in failed auction rate securities.
- Track the commercialization progress and sales contribution of the NanoKnife IRE technology.